CAJ | 학술논문

目的探讨噻托溴铵联合沙美特罗/氟替卡松对稳定期C组慢性阻塞性肺疾病(COPD)患者临床症状及肺功能的改善作用.方法 60例稳定期C组COPD患者随机分为治疗组30例,给予噻托溴铵吸入剂(18 μg,吸入,1次/d)联合沙美特罗/丙酸氟替卡松吸人剂(50μg/500μg,吸入,2次/d)治疗;对照组30例,给予按需吸入异丙托溴铵或沙丁胺醇气雾剂.治疗前、后8周运动耐量的变化及治疗前、治疗后8周后肺功能变化.结果治疗8周后两组6 min步行距离(6MWD)值均较治疗前明显增加,而治疗组中各项指标改善显著优于对照组(P＜0.05).治疗8周后两组FVC、FEV1,和FEV1％pred值均较治疗前明显增加(P＜0.05),治疗组指标改善显著优于对照组(P＜0.05).结论噻托溴铵与沙美特罗/氟替卡松联合吸入治疗稳定期C组COPD患者,优于异丙托溴铵或沙丁胺醇按需吸入治疗.
목적 탐토새탁추안연합사미특라/불체잡송대은정기C조만성조새성폐질병(COPD)환자림상증상급폐공능적개선작용.방법 60례은정기C조COPD환자수궤분위치료조30례,급여새탁추안흡입제(18 μg,흡입,1차/d)연합사미특라/병산불체잡송흡인제(50μg/500μg,흡입,2차/d)치료;대조조30례,급여안수흡입이병탁추안혹사정알순기무제.치료전、후8주운동내량적변화급치료전、치료후8주후폐공능변화.결과 치료8주후량조6 min보행거리(6MWD)치균교치료전명현증가,이치료조중각항지표개선현저우우대조조(P＜0.05).치료8주후량조FVC、FEV1,화FEV1％pred치균교치료전명현증가(P＜0.05),치료조지표개선현저우우대조조(P＜0.05).결론 새탁추안여사미특라/불체잡송연합흡입치료은정기C조COPD환자,우우이병탁추안혹사정알순안수흡입치료.
Objective To investigate the therapeutic effects of combination treatment of tiotropium plus salmeterol and fluticasone in the treatment of stable chronic obstructive pulmonary disease (COPD) patients of group C.Methods 60 subjects with stable COPD in group C classified by combined COPD assessment,were randomly divided into a treatment group (n=30) and a control group (n=30).The treatment group was treated with tiotropium(1 8 μ g,inhalation,once daily) plus salmeterol and fluticasone (50,500 μ g,inhalation,twice a day) and the control group was treated only with ipratropium bromide and albuterol aerosol according to the needs.The exercise tolerance and lung function were measured before and 8 weeks after the treatment respectively.Results 8 weeks after the treatment,there were improvements of 6 minute walk test compared with baseline and the control group,significantly greater improvements in the FVC,FEV1 and FEV1％ pred were seen in the treatment group at all time points(P＜O.05).FVC,FEV1 and FEV1％ pred 8 weeks after treatment were higher than those before treatment in both two groups(P＜O.05),but there was a significant difference between the treatment group and the control group (P＜O.05).Conclusion Combination treatment with tiotropium,salmeterol and fluticasone inhalation has greater therapeutic benefits than ipratropium bromide or albuterol aerosol inhalation alone in stable COPD patients of group C.